600521 Stock Overview
Operates as a pharmaceutical company in China and internationally. More details
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 3/6 |
Financial Health | 4/6 |
Dividends | 4/6 |
Zhejiang Huahai Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥17.51 |
52 Week High | CN¥21.55 |
52 Week Low | CN¥10.71 |
Beta | 0.091 |
11 Month Change | -8.42% |
3 Month Change | 2.64% |
1 Year Change | 9.92% |
33 Year Change | -14.04% |
5 Year Change | 2.56% |
Change since IPO | 95.62% |
Recent News & Updates
Recent updates
Shareholder Returns
600521 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | -2.2% | 1.0% | -0.9% |
1Y | 9.9% | -4.8% | 5.4% |
Return vs Industry: 600521 exceeded the CN Pharmaceuticals industry which returned -4.8% over the past year.
Return vs Market: 600521 exceeded the CN Market which returned 5.4% over the past year.
Price Volatility
600521 volatility | |
---|---|
600521 Average Weekly Movement | 5.5% |
Pharmaceuticals Industry Average Movement | 7.2% |
Market Average Movement | 8.3% |
10% most volatile stocks in CN Market | 12.6% |
10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 600521 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600521's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1989 | 8,221 | Bao Hua Chen | www.huahaipharm.com |
Zhejiang Huahai Pharmaceutical Co., Ltd. operates as a pharmaceutical company in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging components, such as high-density polyethylene bottles and polypropylene caps for pharmaceuticals.
Zhejiang Huahai Pharmaceutical Co., Ltd. Fundamentals Summary
600521 fundamental statistics | |
---|---|
Market cap | CN¥25.37b |
Earnings (TTM) | CN¥1.14b |
Revenue (TTM) | CN¥9.35b |
22.3x
P/E Ratio2.7x
P/S RatioIs 600521 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
600521 income statement (TTM) | |
---|---|
Revenue | CN¥9.35b |
Cost of Revenue | CN¥3.53b |
Gross Profit | CN¥5.81b |
Other Expenses | CN¥4.67b |
Earnings | CN¥1.14b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.79 |
Gross Margin | 62.19% |
Net Profit Margin | 12.20% |
Debt/Equity Ratio | 77.1% |
How did 600521 perform over the long term?
See historical performance and comparison